



## SAFETY DATA SHEET

**Product Name: Oxytocin Injection, USP**

### 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

<b>Manufacturer Name And Address</b>	Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA
<b>Emergency Telephone</b>	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418
<b>Hospira, Inc., Non-Emergency</b>	224 212-2000
<b>Product Name</b>	Oxytocin Injection, USP
<b>Synonyms</b>	Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH <sub>2</sub> cyclic (1@6) disulphide, monoacetate; [2-Leucine,7-isoleucine]vasopressin; 3-Isoleucine-8-leucine vasopressin, monoacetate.

### 2. HAZARD(S) IDENTIFICATION

<b>Emergency Overview</b>	Oxytocin Injection, USP is a solution containing oxytocin monoacetate, a cyclic nonapeptide having the structure of the hormone produced by the posterior lobe of the pituitary. Clinically, oxytocin is used to stimulate uterine contractions and milk ejection. In the workplace, this material should be considered potentially irritating to the skin, eyes, and respiratory tract, a potent drug, a potential reproductive hazard.. Based on clinical use, possible target organs include the cardiovascular system, central nervous system and uterus.
---------------------------	---

#### U.S. OSHA GHS Classification

<b>Physical Hazards</b>	<b>Hazard Class</b>	<b>Hazard Category</b>
	Not Classified	Not Classified
<b>Health Hazards</b>	<b>Hazard Class</b>	<b>Hazard Category</b>
	Not Classified	Not Classified

#### Label Element(s)

**Pictogram** NA

**Signal Word** NA

**Hazard Statement(s)** NA

#### Precautionary Statement(s)

**Prevention** Do not breathe vapor or spray  
Wash hands thoroughly after handling

**Response** Get medical attention if you feel unwell.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Active Ingredient Name** Oxytocin Monoacetate  
**Chemical Formula**  $C_{43}H_{66}N_{12}O_{12}S_2 \cdot C_2H_4O_2$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Oxytocin Monoacetate	0.002	6233-83-6	RS7534000 (Oxytocin)

Non-hazardous ingredients include Water for Injection. Hazardous ingredients present at <1% (w/w) include sodium chloride and sodium acetate. Acetic acid is added for pH adjustment). Chlorobutanol (0.5%) is added as a preservative.

### 4. FIRST AID MEASURES

**Eye Contact** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Skin Contact** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Inhalation** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Ingestion** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

### 5. FIRE FIGHTING MEASURES

**Flammability** None anticipated for this aqueous product.

**Fire & Explosion Hazard** None anticipated for this aqueous product.

**Extinguishing Media** As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam.

**Special Fire Fighting Procedures** No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

**Spill Cleanup and Disposal** Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill control procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.

### 7. HANDLING AND STORAGE

**Handling** No special handling required under conditions of normal use.

**Storage** No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.

**Special Precautions** No special precautions required for hazard control. Women who are in the second or third trimester of pregnancy should be informed of the potential of oxytocin to induce uterine contractions and labor, and should consult a health and/or safety professional prior to working with open containers of this product.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Exposure Guidelines

Component	Exposure Limits			
	OSHA-PEL	ACGIH-TLV	AIHA WEEL	Hospira EEL
Oxytocin monoacetate	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit  
 ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.  
 AIHA WEEL: Workplace Environmental Exposure Level  
 EEL: Employee Exposure Limit.  
 TWA: 8-hour Time Weighted Average.

#### Respiratory Protection

Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

#### Skin Protection

If skin contact with this material is likely, the use of latex or nitrile gloves is recommended.

#### Eye Protection

Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

#### Engineering Controls

Engineering controls are normally not needed during the normal use of this material.

## 9. PHYSICAL/CHEMICAL PROPERTIES

<b>Appearance/Physical State</b>	A clear colorless liquid
<b>Odor</b>	NA
<b>Odor Threshold</b>	NA
<b>pH</b>	~3.9
<b>Melting point/Freezing Point</b>	NA
<b>Initial Boiling Point/Boiling Point Range</b>	NA
<b>Flash Point</b>	NA
<b>Evaporation Rate</b>	NA
<b>Flammability (solid, gas)</b>	NA
<b>Upper/Lower Flammability or Explosive Limits</b>	NA
<b>Vapor Pressure</b>	NA
<b>Vapor Density (Air =1)</b>	NA
<b>Relative Density</b>	NA
<b>Solubility</b>	Very soluble in water and dilute solutions of dehydrated alcohol and of acetic acid
<b>Partition Coefficient: n-octanol/water</b>	NA
<b>Auto-ignition Temperature</b>	NA
<b>Decomposition Temperature</b>	NA
<b>Viscosity</b>	NA

## 10. STABILITY AND REACTIVITY

<b>Reactivity</b>	Not determined.
<b>Chemical Stability</b>	Stable under standard use and storage conditions.
<b>Hazardous Reactions</b>	Not determined
<b>Conditions to Avoid</b>	Not determined
<b>Incompatibilities</b>	Not determined
<b>Hazardous Decomposition Products</b>	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx) and nitrogen oxides (NOx) and sulfur oxides (SOx).
<b>Hazardous Polymerization</b>	Not anticipated to occur with this material.

## 11. TOXICOLOGICAL INFORMATION

**Acute Toxicity** –Not determined for the product formulation. Information for oxytocin is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Oxytocin	100	LD50	Oral	>20.52 >514	mg/kg mg/kg	Rat Mouse
Oxytocin	100	LD50	Intravenous	2.28 5.8	mg/kg mg/kg	Rat Mouse

LD 50: Dosage that produces 50% mortality.

<b>Occupational Exposure Potential</b>	Information on the absorption of this material via inhalation or skin contact is limited. Oxytocin is absorbed when administered as nasal spray/drops or via the buccal route. Avoid aerosol generation and skin contact.
<b>Signs and Symptoms</b>	None anticipated from normal handling of this product. In women, oxytocin acts on smooth muscle in the uterus to induce strong contractions. In clinical use in women, large parenteral doses of oxytocin have produced nausea and vomiting, and severe decreases in maternal blood pressure, accompanied by an increase in heart rate. Hypotension may be followed by weakness, dizziness, and hypertension with a severe headache. Strong uterine contractions and postpartum hemorrhage have also been reported from clinical use. In men, transient headache and flushing have been reported after intravenous bolus or intra-nasal bolus administration. In men, administration of 16 international units (IU) (about 32 mcg) oxytocin by nasal spray produced minor side effects including flushing and a transient slight headache; administration of 300 IU (about 600 mcg) of oxytocin by the buccal route for 14 days did not produce any side effects. In men, administration of 600 IU (about 1200 mcg) per day by the buccal route for a minimum of seven weeks did not produce any effects on blood pressure, pulse rate, or clinical hematology parameters.
<b>Aspiration Hazard</b>	None anticipated from normal handling of this product.
<b>Dermal Irritation/ Corrosion</b>	None anticipated from normal handling of this product.
<b>Ocular Irritation/ Corrosion</b>	None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation with redness and discomfort.
<b>Dermal or Respiratory Sensitization</b>	None anticipated from normal handling of this product.

### 11. TOXICOLOGICAL INFORMATION: continued

<b>Reproductive Effects</b>	None anticipated from normal handling of this product. Animal fertility and/or developmental toxicity studies have not been conducted with oxytocin. In clinical use, strong uterine contractions and postpartum hemorrhage have been reported in patients.
<b>Mutagenicity</b>	Studies to evaluate the mutagenic potential of oxytocin have not been conducted.
<b>Carcinogenicity</b>	Studies to evaluate carcinogenic potential of oxytocin have not been conducted.
<b>Carcinogen Lists</b>	<b>IARC:</b> Not listed <b>NTP:</b> Not listed <b>OSHA:</b> Not listed
<b>Specific Target Organ Toxicity – Single Exposure</b>	NA
<b>Specific Target Organ Toxicity – Repeat Exposure</b>	Based on clinical use, possible target organs include the cardiovascular system, central nervous system and uterus.

### 12. ECOLOGICAL INFORMATION

<b>Aquatic Toxicity</b>	Not determined for product.
<b>Persistence/Biodegradability</b>	Not determined for product.
<b>Bioaccumulation</b>	Not determined for product.
<b>Mobility in Soil</b>	Not determined for product.

Notes:

### 13. DISPOSAL CONSIDERATIONS

<b>Waste Disposal</b>	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
<b>Container Handling and Disposal</b>	Dispose of container and unused contents in accordance with federal, state and local regulations.

### 14. TRANSPORTATION INFORMATION

<b>ADR/ADG/ DOT STATUS</b>	Not regulated
<b>Proper Shipping Name</b>	NA
<b>Hazard Class</b>	NA
<b>UN Number</b>	NA
<b>Packing Group</b>	NA
<b>Reportable Quantity</b>	NA
<b>ICAO/IATA STATUS</b>	Not regulated
<b>Proper Shipping Name</b>	NA
<b>Hazard Class</b>	NA
<b>UN Number</b>	NA
<b>Packing Group</b>	NA
<b>Reportable Quantity</b>	NA
<b>IMDG STATUS</b>	Not regulated
<b>Proper Shipping Name</b>	NA
<b>Hazard Class</b>	NA
<b>UN Number</b>	NA
<b>Packing Group</b>	NA
<b>Reportable Quantity</b>	NA

Notes: DOT - US Department of Transportation Regulations

**15. REGULATORY INFORMATION**

<b>US TSCA Status</b>	Exempt
<b>US CERCLA Status</b>	Not listed
<b>US SARA 302 Status</b>	Not listed
<b>US SARA 313 Status</b>	Not listed
<b>US RCRA Status</b>	Not listed
<b>US PROP 65 (Calif.)</b>	Not listed

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

**GHS/CLP Classification\***

\*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user.

<b>Hazard Class</b>	<b>Hazard Category</b>	<b>Pictogram</b>	<b>Signal Word</b>	<b>Hazard Statement</b>
NA	NA	NA	NA	NA
<b>Prevention</b>	Do not breathe vapor or spray Wash hands thoroughly after handling			
<b>Response</b>	Get medical attention if you feel unwell.  IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.			

**EU Classification\***

\*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive.

<b>Classification(s)</b>	NA
<b>Symbol</b>	NA
<b>Indication of Danger</b>	NA
<b>Risk Phrases</b>	NA
<b>Safety Phrases</b>	S23: Do not breathe vapor/spray S24: Avoid contact with the skin S25: Avoid contact with eyes S37/39 Wear suitable gloves and eye/face protection.

**16. OTHER INFORMATION**

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD <sub>50</sub>	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
STOT - SE	Specific Target Organ Toxicity – Single Exposure
STOT - RE	Specific Target Organ Toxicity – Repeated Exposure
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS  
Date Prepared: October 19, 2012  
Date Revised: June 02, 2014

**Disclaimer:**

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.